Utah Medical Products (UTMD) Cash from Financing Activities (2010 - 2026)

Utah Medical Products' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 73.64% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$9.2 million (up 61.74% YoY), while the FY2025 annual figure was -$12.3 million, up 48.24% from the prior year.
• Cash from Financing Activities was -$1.1 million for Q1 2026 at Utah Medical Products, up from -$2.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $19000.0 in Q1 2022 to a low of -$7.7 million in Q4 2024.
• Historically, Cash from Financing Activities has averaged -$2.8 million across 5 years, with a median of -$1.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 102.0% in 2022, then slumped 5621.05% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$920000.0 in 2022, then declined by 16.41% to -$1.1 million in 2023, then sank by 623.34% to -$7.7 million in 2024, then jumped by 74.56% to -$2.0 million in 2025, then surged by 43.33% to -$1.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$1.1 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.